The Technical Analyst
Cyclerion Therapeutics [CYCN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cyclerion Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.77% $3.32
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.00 mill |
| EPS: | -5.39 |
| P/E: | -0.620 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 2.71 mill |
| Avg Daily Volume: | 0.0030 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.620 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.620 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.24 (-2.46%) $-0.0818 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.06 - 3.58 ( +/- 7.95%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-04 | Chicko Rhonda M. | Sell | 0 | Common Stock |
| 2024-01-01 | Hecht Peter M | Buy | 15 000 | Common Stock |
| 2024-01-01 | Graul Regina Margaret | Buy | 50 000 | Common Stock |
| 2023-11-30 | Katabi Dina | Sell | 0 | Common Stock |
| 2023-11-30 | Higgins Michael J | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 100 transactions |
| Buy: 5 326 508 | Sell: 727 933 |
Forecast:
15:44 - $3.47
Live Trading Signals (every 1 min)
Forecast
1: 14:14 - $3.44
Forecast 2: 15:04 - $3.63
Forecast 3: 15:44 - $3.47
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $3.32 (-3.77% ) |
| Volume | 0.0024 mill |
| Avg. Vol. | 0.0030 mill |
| % of Avg. Vol | 79.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CYCN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2023-12-04 08:00:00 - Press Release
Cyclerion Appoints Regina Graul, Ph.d., As President
– dr. graul will lead the rebuild of cyclerion, bringing more than two decades of drug making experience, r&d portfolio leadership, and a deep expertise in company strategy –
2023-11-30 18:16:00 - Press Release
Cyclerion Strengthens Board Of Directors With Experienced Company Builder And Cutting-edge Innovator
- dina katabi, ph.d.: world leader in healthcare ai applications at mit; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
2023-07-31 07:00:00 - Press Release
Tisento Launches With $81 Million From Top-tier Investor Syndicate And Promising Cyclerion Assets
– asset purchase agreement closed; cyclerion received equity ownership in tisento and upfront cash payment –
2022-06-06 07:00:00 - Press Release
Cyclerion Therapeutics To Share Cy6463 Melas Topline Study Results, Chop To Present Cy6463 Preclinical Data At Umdf Mitochondrial Medicine 2022 Symposium
Topline results to be shared during the clinical trial update platform session
2021-09-22 08:00:00 - Press Release
Cyclerion Announces Publication Of Preclinical Data Demonstrating Reduction In Neuroinflammation By Brain-penetrant Sgc Stimulator
Company developing lead sgc stimulator, cy6463, in multiple cns diseases associated with cognitive impairment company developing lead sgc stimulator, cy6463, in multiple cns diseases associated with cognitive impairment
Latest News
2022-08-09 18:48:09 - Zacks Investment Research
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-06-17 11:27:03 - Benzinga
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
Cyclerion Therapeutics Inc's (NASDAQ: CYCN) preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease. The data will be presented at the.
2022-06-06 07:00:00 - GlobeNewsWire
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
2021-12-15 11:35:17 - Zacks Investment Research
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2021-10-26 16:29:42 - Seeking Alpha
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration.
2021-10-24 14:30:00 - PennyStocks
Trending Penny Stocks to Buy Now? 5 to Watch This Week
Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?
2021-09-22 08:00:00 - GlobeNewsWire
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment
2021-08-23 17:00:00 - GlobeNewsWire
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit
Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies
2021-07-29 17:00:00 - GlobeNewsWire
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment
2021-07-22 16:30:00 - GlobeNewsWire
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)
Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics